Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice

Cancer Research

Volumn 69, Issue 7, 2009, Pages 2853-2860

  Vincent, François ^a,c   Bonnin, Philippe ^a   Clemessy, Maud ^a   Confreres, Jean Olivier ^a,b   Lamandé, Noël ^a   Gase, Jean Marie ^a   Vilar, José ^a   Hainaud, Patricia ^a,b   Tobelem, Gérard ^a,b   Corvol, Pierre ^a   Dupuy, Evelyne ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSINOGEN; EPHRIN B2; LIGAND; NOTCH4 RECEPTOR; TUMOR MARKER; DLL4 PROTEIN, MOUSE; MEMBRANE PROTEIN; MESSENGER RNA; NOTCH RECEPTOR; NOTCH4 PROTEIN, MOUSE; ONCOPROTEIN; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD FLOW VELOCITY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DENSITY; DRUG BLOOD LEVEL; EMBRYO; FEMALE; GENE OVEREXPRESSION; IN VIVO STUDY; LIVER BLOOD FLOW; LIVER CELL; LIVER CELL CARCINOMA; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CELL GROWTH; GENETICS; HUMAN; LIVER; LIVER TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; VASCULARIZATION;

ANGIOTENSINOGEN; ANIMALS; CELL GROWTH PROCESSES; EPHRIN-B2; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS; RECEPTORS, NOTCH; RNA, MESSENGER;

EID: 66149133341     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2484     Document Type: Article

References (37)

1. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-660.
2. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-974.
3. Jain RK. Normalization, of tumor vasculature: an emerging concept in antianglogenic therapy. Science 2005;307:58-62.
4. Célérier J, Cruz A, Lamande N, Gase JM, Corvol P. Angiotensinogen and its cleaved derivatives inhibit angiogenesis. Hypertension. 2002;39:224-228.
5. Brand M, Lamande N, Larger E, Corvol P, Gase JM. Angiotensinogen impairs angiogenesis in the chick chorioallantoic membrane. J MoI Med 2007;85:451-460.
6. Tewksbury D. Angiotensinogen: biochemistry and molecular biology. In: Laragh JH, Brenner GM, eds. Hypertension. New York: Raven Press; 1990. p. 1197-1216
7. Corvol P, Jeunemaitre X. Molecular genetics of human hypertension: role of angiotensinogen. Endocr Rev 1997; 18:662-677.
8. Celerier J, Schmid G, Le Caer JP, et al. Characterization of a human angiotensinogen cleaved in its reactive center loop by a proteolytic activity from Chinese hamster ovary cells. J Biol Chem 2000:275:10648-10654.
9. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antianglogenic activity of the cleaved conformation of the serpin antithrombin Science 1999;285:1926-1928.
10. Zhang M1 Volpert O Shi YH Bouck N. Maspin is an angiogenesis inhibitor. Nat Med 2000;6:196-199.
11. Dawson DW, Volpert OV GiUis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-248.
12. Miao RQ, Agata J, Chao L, Chao J. Kallistatin. is a new inhibitor of angiogenesis and tumor growth. Blood 2002; 100:3245-3252.
13. Bouquet C, Lamande N, Brand M1 et al. Suppression of angiogenesis, tumor growth, and metastasis by adenovirus-mediated gene transfer of human, angioten-sinogen. MoI Ther 2006;14:175-182
14. Yang G, Merrill DC, Thompson MW, Robillard JE, Sigmund CD. Functional, expression of the human angiotensinogen gene in transgenic mice. J Biol Chem 1994;269:32497-502.
15. Dubois N, Bennoun M, Allemand I, et al. Time-course development of differentiated hepatocarcinoma and lung metastasis in transgenic mice. J Hepatol 1991;13:227-39
16. Dupuy E, Hainaud P, Villemain A, et al. Tumoral angiogenesis and tissue factor expression during hepatocellular carcinoma progression in. a transgenic mouse model. J Hepatol 2003:38:793-802.
17. Lawson ND, Scheer N1 Pham VN1 et al. Notch signaling is required for arterial-venous differentiation during embryonic vascular development. Development 2001;128:3675-3683.
18. Carlson TR, Yan. Y, WuX et al. Endothelial expression of constitutively active Notch4 elicits reversible arterio- venous malformations in adult mice. Proc Natl Acad Sei USA 2005;102:9884-9889.
19. Gale NW Baluk P Pan L et al. Ephrin.-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression, in both endothelial, and smooth-muscle cells. Dev Biol 2001;230:151-160.
20. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL. Up-regulation of Delta-like 4 ligand In human tumor vasculature and the role of basal expression, in endothelial, cell function. Cancer Res 2005;65:8690-8697.
21. Hainaud P, Confreres JO, Villemain A, et al. The role of the vascular endothelial growth factor-Delta-Iike 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res 2006;66:8501-8510.
22. Bonnin P, Villemain A, Vincent F, et al. Ultrasonic assessment of hepatic blood flow as a marker of mouse hepatocarcinoma. Ultrasound Med Biol 2007;33:561-570.
23. Sibony M, Commo F, Callard P1 Gase JM. Enhance- ment of mRNA in situ hybridization signal by micro- wave heating. Lab Invest 1995;73:586-591.
24. Clauser E, Bouhnlk J, Jaramillo HN, Auzan C, Corvol P, Menard J. Angiotensinogen production and consump- tion in the adrenalectomized rat. Endocrinology .1985;11.6:274-280.
25. Menard J, Catt KJ. Measurement of renin activity, concentration and substrate in rat plasma by radioim- munoassay of angiotensin I. Endocrinology 1972:90: 422-30.
26. Sugimoto H, Kaneko T1 Hirota M1 Inoue S1 Takeda S1 Nakao A. Physical hemodynamic Interaction between, portal venous and hepatic arterial blood flow in humans. Liver Int 2005;25:282-287.
27. Straub AC, Stolz DB, Ross MA, et al. Arsenic stimulates sinusoidal endothelial cell capUlarization and vessel remodeling in mouse liver. Hepatology 2007;45:205-212.
28. Li JL, Salmon RC, Shi W et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 2007;67:1.1.244-53.
29. Ridgway J, Zhang G1 Wu Y1 et al. Inhibition of DU4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006;444:1083-1087.
30. Noguera-Troise I1 Daly C1 Papadopoulos NJ1 et al. Blockade of Dl.1.4 Inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444:1032-1037.
31. Gale NW Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999;13:1055-1066.
32. Wang HU, Chen ZF, Anderson DJ. Molecular distinction, and angiogenic interaction, between embry- onic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. CeU 1.998:93:741-753.
33. Harrington. LS, Sainson. RC, Williams CK, et al. Regulation of multiple angiogenic pathways by DU4 and Notch in. human umbilical vein endothelial, cells. Microvasc Res 2008;75:144-154.
34. Brand M, Lamande N, Sigmund CD, Larger E, Corvol P, Gase JM. Angiotensinogen modulates renal, vasculature growth. Hypertension 2006:47:1067-1074.
35. Thorgeirsson. SS, Grisham. JW. Molecular pathogen-esis of human, hepatocellular carcinoma. Nat Genet 2002;31:339-346.
36. Zhang M, Shi Y, Magit D1 Fürth PA1 Sager R. Reduced mammary tumor progression in WAP-TAg/WAP-maspin bitransgenic mice. Oncogene 2000:19*053-8.
37. Cai J1 Jiang WG1 Grant MB1 Boulton M1 Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothe- lial growth factor receptor 1. J Biol Chem 2006:281: 3604-13.